survey high-volum urologist gaug potenti urolift
rezum find urolift procedur mix expect reach
two year current mix rezum expect
two year adopt driven patient outcom econom
urolift take share modal includ drug therapi
rezum gain share surgery/abl rais
survey goal gaug demand urolift rezum bph market
market bph treatment signific men activ treat us
treat surgicallytot spend bph treatment new
bph therapi recent enter mix urolift system acquir late
rezum system acquir earlier year survey explor
demand outlook two emerg bph treatment
urolift rezum pois signific growth sampl urologist
report increas rezum system adopt sinc growth adopt
sinc urolift importantli adopt trend track surpass
support good growth technolog current util among respond
survey urolift procedur per month procedur per month
rezum urologist indic monthli util expect rise next two year
technolog
urolift potenti first-lin therapi respons efficaci show substanti benefit
versu drug therapi surgical/abl techniqu particularli around time-to-first
evid symptom improv sustain symptom improv lower
incid sexual dysfunct find similar publish data respond
indic urolift bph patient come activ drug therapi
modal
rezum posit gain vs surgeri ablat physician ease-of-us faster
learn curv perman tissu disrupt note key adopt driver
respond indic rezum well posit gain versu surgic turp
tuip abl pvp technolog near-term respond indic higher
adopt depend payment rate pend code effect jan
implic growth outlook base/bul
case rezum call contribut base/bul
case urolift call contribut base
estim rezum urolift add organ top-lin growth profil
support recent issu outlook
market award high-growth med-tech asset contribut
rezum urolift support premium valuat versu peer
rais find survey support top-pick base
survey work rais forecast urolift
revis target go prior rais
forecast rezum see estimate chang note
revis ep target ahead street consensu
revis ep target line street consensu
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
conduct survey us-
gaug demand/purchas trend
urolift rezum system
potenti share gain versu
survey respons indic rezum
potenti share gain versu
surgical/abl therapi
urologist report increas
urolift/rezum system adopt
util increas year
conduct survey us-bas urologist better understand demand
util trend recent acquir urolift boston scientif recent
acquir rezum system respond high-volum site averag
activ bph monthli visit consultation/treatment/follow-up either
awar activ use urolift and/or rezum respect practic
urolift find potenti candid first-lin therapi
respons efficaci show substanti benefit use urolift versu drug therapi
surgical/abl techniqu particularli around time-to-first evid
symptom improv sustain symptom improv lower incid
sexual dysfunct find similar publish data respond indic
urolift bph patient come activ drug therapi
modal indic strong potenti displac earlier line therapi
rezum find posit gain vs surgeri ablat
respons efficaci show similar benefit reduc incid key side effect
includ sexual dysfunct off-set longer-dur initi symptom relief onset
asid patient outcom benefit physician ease-of-us faster learn curv
perman tissu disrupt note key adopt driver respond
indic rezum well posit gain versu surgic turp tuip
abl pvp technolog near term respond indic higher
adopt depend payment rate attach pend categori code
urolift vs rezum differ end target plenti room technolog
physician feedback clear system target distinct area urolift earlier-stag
patient rezum later-stag patient henc see dual roll zero-
sum game situat said see urolift attract growth
opportun given potenti gain share drug therapi patient versu
rezum target surgery/abl patient
rais find survey support top-pick
rais forecast urolift bake
contribut rezum forecast bull
case scenario call increment upsid potenti system
chart neotract estimate chang base survey
chart endosurgeri estimate chang base survey
jefferi estim figur million
jefferi estim figur million
page
pleas see import disclosur inform page report
chart site heavili focus treat bph
survey summar chart
chart urolift adopt increas survey site
chart rezum hyper-growth phase survey site
chart urolift/rezum adopt driven improv
patient outcom vs soc therapi
chart monthli procedur expect rise
page
pleas see import disclosur inform page report
respondentsmonthli patient visitsoursurvey sought respons high-volum urolog practic order captur earli adopt trend urolift respondentsbph total monthli patient visitsthebulk patient visit site captur surveri heavili focus treat ytd urolift adopt yearurolift adopt increas among urologist sampl largest inflect ytd rezum system adoptionsrezum adopt sharpli increasedin high rate also report incid urinari retention perform local anesthesiapati demand uroliftfavor reimbursementlong sustain symptom improvementrisk follow-up visit perform office/asc settingproduct eas usereduc incid sexual dysfunctionpati procedur experiencepati post recoveri satisfactionfast time patient relief onsetour respond indicatedthat reimburs among lowest driver urolift rezum uroliftwa year year fromnowmonthli procedur volumerespondentsexpect monthli urolift procedur nearli tripl next practic healthcar
rais urolift forecast base survey find
given result survey econom play prior forecast
urolift revenu rais number busi reflect believ
like growth trajectori current assumpt use conjunct
physician expect survey show declin market penetr
wherea appear clear urolift continu gain share come year
chart urolift contribut bake prior revenu forecast
one conserv assum flat penetr trend combin
expect around procedur volum averag practic awar urolift
grow upsid could signific follow step show upsid prior
number initi number alreadi compani
beat mileston
chart impli urolift contribut use util penetr feedback survey
page
pleas see import disclosur inform page report
urolift per per urolift revenu urolift revenu per urologist neotract revenu urologist target impli penetr urolog survey impli urolift penetr base survey prior estimatessourc urolog survey monthli urolift implant higher neotract econom analysiscommentsour prior estim neotract exceed milestoneurolift per per urolift revenu urolift revenu per urologist target penetr implant neotract revenu neotract revenu revis vs prior urolog survey penetr like increas provid addit upsideour survey point toward upsideurolift econom monthli urolift implant higher neotract forecastsourc urolog survey scenario exce milesteon year earli healthcar
base case take conserv approach procedur growth assum
modest growth penetr year assumpt show upsid
period case alon allow neotract reach
howev also reason assum penetr could occur even higher
rate roughli market share gain annual scenario differ
even larger spread delta initi estim
level mileston pass larg margin year prior
target place
page
pleas see import disclosur inform page report
urolift per per urolift revenu urolift revenu per urologist target penetr implant neotract revenu neotract revenu revis vs prior base case assum annual gain uroliftest monthli urolift implant higher neotract forecastour revis base case bake urolift upsidecommentssourc urolog survey urolift econom exce milesteon year earlymoder gain util vari wide survey suggestionsurolift per per urolift revenu urolift revenu per urologist target penetr implant neotract revenu neotract revenu revis vs prior base case point toward urolift econom analysisest monthli urolift implant higher neotract forecastscenario vastli exce milesteon almost year earlyour bull case assum annual gain uroliftmoder gain util vari wide survey suggestionssourc urolog survey healthcar
increas rezum forecast survey
given addit insight survey believ make reason
assumpt trajectori rezum includ model prior estim
assum contribut revis estim assum run rate similar
urolift although view urolift slight favorit urolog practic
treatment count penetr number reflect base case assum
growth moder util gain lower base urolift
similarli includ bull case rezum consist market share gain
year slightli faster util growth justifi base compani
larger sale presenc urology/men space assumpt lead nearli
increment revenu base case assumpt exit
page
pleas see import disclosur inform page report
rezum per per rezum revenu rezum revenu per urologist target penetr implant rezum revenu revis base case bake rezum rezum econom rate sourc urolog surveyprocedur growth follow similar ramp uroliftsourc aua medgadget bloomberg transcriptsbas case assum annual rezum slightli behind uroliftrezum per per rezum revenu rezum revenu per urologist target penetr implant rezum revenu case rezum revenu revis vs prior bull case see rezum upsid potenti commentsgrowth rate sourc urolog surveyslightli faster procedures/month outer yearssourc aua medgadget bloomberg transcriptsour bull case assum annual gain start revenu assum purchas price sale rezum econom healthcar
bph treatment altern fall sever major categori either stage
directli indic base sever case treat first line therapi
watch wait variou drug therapieshav limit accur gaug
diseas progress control symptom deliv relief case drug
develop unwant side effect
advanc therapiesminim invas surgeri ablat techniqueshav
mix result effect treat symptom along high rate unwant side
effect includ reintervent hospit despit limit littl
innov taken place bph space sinc launch greenlight
laser abl therapi use pvp energi proven durabl despit similar rate
side effect turp surgic intervent greenlight acquir boston
scientif am transact
approxim men us moder sever symptom bph
activ manag men drug
drug drop out men suffer bph undergo surgeri
undergo surgeri yearput surgic volum procedur per
year remain watch wait
chart share bhp treatment procedur
neotract nxthera fill void innov develop urolift fda
clear sept rezum system fda clear sept
show earli potenti becom new standard care versu mi intervent
possibl drug overtim exit valuat neotract acquir
oct nxthera acquir boston scientif april
indic technolog growth potenti rezum urolift attempt
avoid shortcom surgic procedur avoid tissue-destruct
manner caus undesir side effect sexual dysfunct
two approach differ urolift avoid destroy tissu altogeth use
deliveri devic enter urethra urolift devic place implant obstruct
prostat tissu hold away urethr open improv symptom
short period time rezum system vapor tissu attempt without
trigger side effect seen abl techniqu rezum deliv vapor
steam obstruct site gradual kill excess prostat tissu cell
page
pleas see import disclosur inform page report
chart urolift rezum product descript
page
pleas see import disclosur inform page report
laser photoselect burn away excess tissue ejaculatori dysfunct holeplas vapor excess tissu enucl ejaculatori dysfunct tuipwiden urethra make cut bladder neck prostat gland incontin holaplas incis bladder neck made reduc pressur urethra ejaculatori dysfunct tunaurethra deliv needl emit low-energi radiofrequ ablat tissue ejaculatori dysfunt tumturethra deliv microwav antenna emit microwav dose energi ablateurinari tuvploop groov electrod roller insert remov excess tissueejaculatori dysfunct turpelectr current sharp dissect object insert urethra ejaculatori dysfunct inhibitor drug decreas detrusor prostat urethra smooth muscl ton via increas intracellular cgmp infect dysepspia combin combin mechan action use alpha blocker ed ejaculatori dysfunct hypotens alpha blocker drug design relax tension prostat smooth muscl target alpha-receptor ed ejaculatori dysfunct mra drug decreas bladder smooth muscl cell contract inhibit muscarin ari drug block growth prostat cell taget reductas enyzm decreas concentr ed ejaculatori dysfunct blur rezumus steam ablat allow bodi dispos excess tissu natur ejaculatori carrier-pr carrier-pr urolifturethra deliveri impant hold prostat prevent obstruct ejaculatori patient bph treatmenttreat descriptionmajor side effectssexu dysfunct preval treatment healthcar
survey high-volum urologist
screen urologist least practic experi high volum
center treatment mix heavili weight toward bph patient final sampl
urologist averag practic experi center patient
volum heavili skew toward per week bph patient mix averag per
week across final sampl major fall rang
chart mani patient see per week
chart activ symptomat bph patient
given scope survey focus demand trend urolift
boston scientif rezum system screen urologist either activ use
experi technolog urolift specif survey
urologist perform procedur per month perform per month
perform greater per month
chart bph patient treat
follow approach
chart mani bph patient treat
urolift past month
page
pleas see import disclosur inform page report
waitingdrug healthcar
drug therapi util
treatment option bph despit
level efficaci
bph drug therapi rang
per year carri side
effect result high patient
background bph drug therapi
current treatment paradigm moderate-to-sever bph aua-si score call
activ medic manag via variou drug therapi approach among estim
bph preval pool us diagnos and/or activ treat drug therapi
util versu watch wait surgeri despit high presenc advers
effect patient drop-out neotract estim patient drop-off drug therapi
year urolift rezum posit intermedi altern
drug therapi surgic intervent henc target drug-drop popul
directli howev technolog favor safety/efficaci profil versu
mani drug therapi directli see potenti share gain versu activ drug
manag overtim estim patient per year given expans
natur collect opportun take closer look common drug treatment
path prescript volum util trend across physician sampl
common prescrib drug activ bph manag alpha-adrenerg
antagonist mra inhibitor drug distinct
mechan action moa work vari level efficaci sacrific
common side effect drive estim drop-off rate commonli
hytrin rapaflo indic moderate-to-sever symptomat bph regardless
prostat size work relax bladder/prost muscl widest array
inclus sexual dysfunct ed abnorm ejacul alpha-reductas inhibitor
avodart proscar also indic moderate-to-sever symptomat bph
coupl enlarg prostat drug work decreas dihydrotestosteron
product turn limit prostat cellular growth also lead variou
form sexual dysfunct hormon imbal gynecomastia list side
effect mra detrol toviaz prescrib advanc case diagnos
bph combin overact bladder oab symptom urg incontin nocturia
inhibitor grant label extens treat bph regardless pre-exist
erectil dysfunct ed carri distinct side-effect cost standpoint drug
therapi prescrib monthli rang per year depend
chart list drug therapi moderate-to-sever bph medic manag
page
pleas see import disclosur inform page report
alfuzosin mg detrol mgblock growth prostat cell target enzym decreas concentrationsdutasterid avodart finasterid impair abnorm ejacul erectil dysfunct mastalgia yearli alpha-blockersrelax tension prostat smooth muscl target alpha-receptorserectil dysfunct abnorm ejacul dizzi headach orthostat hypotens fatigu infect qt interv prolong polydipsia ifisclassmechan action moa drug brand daili dose oral advers awp mrasdecreas bladder smooth muscl cell contract inhibit muscarin receptorsxerostomia dri detrusor prostat urethra smooth muscl tone via increas intracellular cgmptadalfil mgback pain dysepspia flush headach infect myalgia nausea combin moa alpha-block see dutasteride-tamsulosin jalyn healthcar
chart illustr mix trend dollar trend brand gener bpg
drug overal mix steadili shift toward gener account
total prescript averag wholesal price awp valu prescrib bph medic
close exit grow compound-annual-growth-rate past
page
pleas see import disclosur inform page report
physician report averag
therapi figur
compar drop-off rate
report neotract
explor prescript drug trend across sampl urologist get sens
drop-off rate see repres signific share captur opportun
urolift rezum prescript mix across sampl mirror broader trend
report symphoni health alpha-block preval follow
drug drop-off rate averag report high
across sampl figur notabl higher report survey
conduct neotract show overal drop-out rate
chart bph drug prescript mix across doc sampl
chart patient drug drop-out across doc sampl
punch-lin ww drug
urologist sampl reli
heavili watch wait
share
captur urolift rezum
urologist survey indic inadequ relief chronic intak regim
cost side effect lead trigger drug drop-off peal
back bit time major urologist indic see patient
drop-off within commenc therapi nearli report drop-
out within collect find signific sinc indic
prefer first-lin therapi treat bph patient medic signific
limit inadequ relief cost side effect open opportun
urologist explor altern urolift rezum
chart average time drop-off drug therapi
page
pleas see import disclosur inform page report
alpha sampl urologist reportedan averag drug-drop rate inclus half rang mosour sampl urologist reportedavg time drug drop-off within efficacytrx regimecostotherour sampl urologist reportedlow efficaci chronic drug regim lead driver drop-off healthcar
come high cost high
incid unwant side effect
background bph surgeri ablat
watch wait activ drug therapi next categori option avail
urologist bph treatment paradigm seri minim invas intervent
either surgic abl intervent remov excess prostat tissu
trans-urethr procedur tissu destruct case ablat
surgeri side common mi techniqu transurethr resect
prostat turp procedur remov part prostat
resectoscop urethra resectoscop long small valv
control irrig fluid electr loop cut tissu seal blood vessel
turp procedur annual us similar therapi turp
transurethr incis prostat tuip instead remov excess prostat tissu
procedur widen urethra make cut bladder neck prostat
gland ablat techniqu use variou energi sourc destruct excess tissu
seal blood vessel transurethr vapor tuvp use heat electr current
transurethr microwav therapi tumt insert small antenna urethra
emit dose microwav energi heat destroy excess tissu transurethr
needl ablat tuna use low energi radio frequenc ablat tissu laser
techniqu use laser ablat tissu includ holmium laser enucl prostat
holep similar procedur turp use vapor tissu holmium laser
ablat prostat holap insert rectoscop prostat laser excess
tissu photoselect vapor prostat pvp insert pvp laser
cystoscop peni guidanc imag vapor tissu like
holep procedur cost standpoint mi techniqu rang per
procedur account reintervent follow-up visit advers event
mi option give relief patient side effect signific common side
effect bleed oper surgeri retrograd ejacul less
format restrict urin flow urinari incontin lower urinari tract symptom
lut infertil due retrograd there ejacul natur insemin
chart list minim invas procedur treatment bph
page
pleas see import disclosur inform page report
vapor excess tissu enucl ejaculatori dysfunct pvpimage-guid laser photoselect burn away excess tissue ejaculatori dysfunct holaplas incis bladder neck made reduc pressur urethra ejaculatori dysfunct tuipwiden urethra make cut bladder neck prostat gland incontin tunaurethra deliv needl emit low-energi radiofrequ ablat tissue ejaculatori dysfunt tumturethra deliv microwav antenna emit microwav dose energi ablateurinari tuvploop groov electrod roller insert remov excess tissueejaculatori dysfunct turpelectr current sharp dissect object insert urethra ejaculatori dysfunct rezumus steam ablat allow bodi dispos excess tissu natur ejaculatori carrier-pr carrier-pr urolifturethra deliveri impant hold prostat prevent obstruct ejaculatori patient bph treatmenttreat descriptionmajor side effectssexu dysfunct preval treatment healthcar
surgic abl techniqu
treat bph mix result
symptom relief coupl high
rate unwant side effect
surgeri ablat lot unwant side effect
drug fail relieve/revers bph symptom deem inadequ advanc
repeat case next categori treatment option varieti minim invas
approach use either surgic abl techniqu approach
surgeri preval account total case within non-drug
categori across urologist practic captur survey ablat account
total case within non-drug categori
chart overal bph treatment mix across sampl
chart non-drug therapi treatment mix survey
punch-lin surgery/abl
surgeri turp/tuip ablat
tumt/tuna high report
complic lut ed ej
urolift rezum shown
improv
although heavili reli upon intervent drug failur advanc bph
case surgical/abl therapi high report rate unwant
side effect variou form sexual dysfunct ejaculatori
erectil dysfunct lower urinari tract symptom lut poll urologist
survey found preval rate combin sexual
dysfunct lut side effect
chart preval side effect bph surgeri
chart preval side effect bph ablat
page
pleas see import disclosur inform page report
waitingdrug dysunct sexual stress incontinenceblood transfusionurinari tract infect uti ureth strictureurinari retent lut irrit void lut ejaculatori dysunct sexual sexualdysfunct lower urinari tract symptom lut common side effect report bph surgeri transfusionstress incontinenceerectil dysunct sexual ureth strictureurinari tract infect uti ejaculatori dysunct sexual urinari retent lut irrit void lut lower urinari tract symptom lut sexual dysfunct common side effect report bph ablat healthcar
given signific limit across major standard care soc treatment categori
bph drug surgeri ablat coupl notabl improv efficaci form
sustain relief lower side effect urolift rezum explor vari
measur effect head-to-head basi across sampl physician
urolift consid new treatment categori altogeth prostat urethr lift
potenti elev first-lin option ask sampl urologist
compar variou measur efficaci side effect patient treat w/urolift
versu two lead bph drug categori alpha-block ab
efficaci urologist report signific benefit time-to-first relief urolift
week versu drug averag well sustain symptom improv
urolift rank scale versu drug better
head-to-head comparison
higher versu drug term initi
sustain symptom relief
chart time-to-first evid relief scale week
urologist report lower rate
sexual dysfunct urolift patient
side effect isol two report measur sexual dysfunct
ejaculatori dysfunct erectil dysfunct similar lift studi
urologist report significantli lower rate sexual dysfunct patient treat
chart preval onset ejaculatori dysfunct
chart preval onset erectil dysfunct
page
pleas see import disclosur inform page report
first evid relief week urologistsreport faster time statist signific relief urolift week versu drug average rank effet urologistsreport highest level symptom improv urolift rel drug therapi significantli lower preval ej pateint treat w/urolift versu drug therapi average significantli lower preval ed pateint treat w/urolift versu drug therapi average healthcar
head-to-head comparison
unwant side effect urolift
rezum show signific benefit
survey urologist sampl
ask urologist compar common side effect urolift rezum versu
minim invas surgeri ablat overal incid level vari time
interv post intervent high rate variou form sexual dysfunct
ejaculatori erectil dysfunct lower urinari tract symptom lut well
accept side effect minim invas treatment option bph first ask
urologist report preval level sever measur side effect one year
post intervent urologist report combin preval ejaculatori
erectil dysfunct surgeri patient combin preval ablat
patient similarli urologist report preval two common form
report lut irrit void urinari retent surgeri patient
ablat patient preval level side effect rang stress
incontin urinari tract infect uti similar surgeri ablat
chart common side effect surgeri patient
chart common side effect ablat patient
urolift rezum show biggest
benefit lower sexual dysfunct
versu surgeri ablat
urolift rezum show similar level lut notabl lower level sexual
dysfunct one year post intervent preval lut high urolift
rezum howev drop-off sexual dysfunct signific combin
report rate ejac ed urolift rezum treat patient
chart common side effect urolift patient
chart common side effect rezum patient
page
pleas see import disclosur inform page report
dysunct sexual stress incontinenceblood transfusionurinari tract infect uti ureth strictureurinari retent lut irrit void lut ejaculatori dysunct sexual sexualdysfunct lower urinari tract symptom lut common side effect report bph surgeri transfusionstress incontinenceerectil dysunct sexual ureth strictureurinari tract infect uti ejaculatori dysunct sexual urinari retent lut irrit void lut lower urinari tract symptom lut sexual dysfunct common side effect report bph ablat transfusionerectil dysunct sexual ejaculatori dysunct sexual stress incontinenceotherurinari tract infect uti urinari retent lut irrit void lut uroliftha similar level report lut show reduct sexual dysfunct side dysunct sexual ejaculatori dysunct sexual stress incontinenceotherureth strictureurinari tract infect uti urinari retent lut irrit void lut rezum hadhigh demonstr incid lut across urologist survey similar level improv sexual dysfunct healthcar
also explor incid common side effect immedi post intervent within
six week signific improv urolift rezum treat patient
report rel specif surgic abl therapi turp pvp tumt
chart post-surg incid urinari retent
chart post-surg incid stress incontin
chart post-surg incid blood transfus
chart post-surg incid urethr strictur
chart post-surg new onset ejac dysfunct
chart post-surg new onset erectil dysfunct
page
pleas see import disclosur inform page report
pvp turpurologistsreport significantli lower level ejac dysfunct urolift rezum pvp turpurologistsalso report significantli lower level erectil dysfunct urolift rezum healthcar
earli technolog adopt well
balanc urolift
rezum w/slight edg latter
earli adopt trend slight edg urolift
survey target high volum urolog practic gaug still consid earli
adopt trend urolift rezum system given early-stag statu
technolog predecessor compani nxthera neotract
privately-held neotract acquir oct receiv de novo
approv fda urolift sept follow soft launch later year
privately-held nxthera acquir april receiv
initi clearanc rezum system sept data survey coincid
timelin sampl urologist report steadili rise adopt
urolift date back inflect adopt pattern rezum
time-frame limit recal devic recal due report failur
needl bond upon deploy technolog appear pois continu growth
chart adopt urolift practic
chart adopt rezum practic
current util favor
urolift procedur per month
although rezum slight edg urolift term new practic adopt de
novo locat rezum vs urolift ytd current util trend
favor urolift across sampl urologist report averag procedur per
month versu rezum importantli figur compar combin
procedur bph treatment approach ww drug surgeri ablat
chart average bph treat patient per week sampl
page
pleas see import disclosur inform page report
